REG - Argent Biopharma Ltd - ASX & LSE Listing Update

Argent BioPharmaAnnouncement

29/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241129:nRSc1046Oa&default-theme=true

RNS Number : 1046O  Argent Biopharma Limited  29 November 2024

 

29 November 2024

 

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

ASX Delisting Update

and

Notice of Intention to Delist from the London Stock Exchange

 

Argent BioPharma, an innovative multidisciplinary drug discovery company
within the biopharmaceutical sector, wishes to advise, that following a
detailed review of both the listing requirements and costs associated with the
transfer of all its ordinary shares, from the equity shares (international
commercial companies secondary listing) category of the Official List
maintained by the Financial Conduct Authority ("FCA") ("Official List"), to
the equity shares (commercial companies) ("ESCC") category of the Official
List, the Company has decided to retain its listing on the Australian
Securities Exchange ("ASX") and apply to the FCA and the London Stock Exchange
("LSE")  to cancel the admission of Argent BioPharma's shares to listing in
the International Commercial Companies Secondary Listing category of the
Official List of the FCA and trading under the ticker "RGT" on the Main Market
for listed securities of the LSE.

 

The Company hereby gives notice that, in an effort to streamline and simplify
processes and increase administrative efficiencies, it will requested that (i)
the FCA cancel the listing of the Company's ordinary shares of NPV ("Shares")
on the equity shares international commercial companies secondary listing
segment of the Official List of the FCA, and (ii) the LSE cancel the admission
to trading of the Company's Shares on the main market for listed securities of
the LSE (collectively, the "Delisting").

 

In accordance with UK Listing Rule 21.2.17, Argent BioPharma is required to
give at least 20 business days' notice of the intended Delisting. It is
expected the Delisting will become effective from 08:00 (GMT) on 31 December
2024. The last day of trading of Argent BioPharma shares on the LSE will be
Monday, 31 December 2024.

 

As the Company is assigned to the equity shares international commercial
companies secondary listing segment of the Official List, no shareholder
approval is required for the Delisting. Following the Delisting, (i) it will
no longer be possible to trade Shares on the LSE, and (ii) the Company will
maintain its listings on the ASX and OTCQB Venture Market.

 

Any shareholder with questions regarding the Delisting is encouraged to
consult their investment adviser or broker. The Company will provide an update
to holders of its Depositary Interests, outlining how their holdings will be
affected and the steps required to ensure the future tradability of their
securities.

 

The Company's main operations and management are based in the EU, with a
growing investor base in the United States of America. Looking ahead, Argent
BioPharma may still look to explore opportunities to expand its accessibility
to investors, including the potential for a dual listing on a United States
based exchange.

 

 

-Ends-

 

 

 

Authorised for release by the board of directors, for further information
please contact:

 

 Argent BioPharma                                             Argent BioPharma

 Roby Zomer                                                   Rowan Harland

 CEO & Managing Director                                      Company Secretary

 +61 8 6555 2950                                              +61 8 6555 2950

 info@argentbiopharma.com (mailto:info@argentbiopharma.com)   info@argentbiopharma.co (mailto:info@argentbiopharma.co.uk) m

About Argent BioPharma

 

Argent BioPharma Limited (the "Company") (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an
innovative multidisciplinary drug development Company within the
biopharmaceutical sector.  The Company focuses on multidisciplinary methods
with Nanotechnology, developing multi-target therapies for comprehensive
disease management, especially concerning the central nervous system ("CNS")
and Immunology treatments.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFVVLLLTFIS